Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

Phase 2 Active not recruiting

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

57 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

BreastGastrointestinalThoracic

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

86 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

200 enrolled

Locoregional Recurrence

NCT06188520 2026-04-08

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Phase 4 Active not recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

300 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 3 FDA

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

3,902 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Dermatologic

Melanoma

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02780128 2026-03-10

NEPENTHE

Phase 1 Terminated

66 enrolled

CNS

Neoplasms, Neuroblastoma

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

20 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms

NCT02933736 2026-03-06

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

48 enrolled

CNS

Glioblastoma, Meningioma

NCT05768139 2026-03-02

PIKALO-1